PDCD1 and neoplasm: In another study, the addition of anti-RANKL (receptor activator of nuclear factor kappa beta) to the combination therapy of anti-PD-1 and anti-CTLA-4 led to enhanced anti-tumor responses, regardless of the ability of anti-CTLA-4 isotype to engage activating Fc receptors 196.